Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575080 | 1.00 | FAAH (0.49) | FAAHSMN1; SMN2ROCK2PRKG1KIT | |
| SCHEMBL4075708 | 1.00 | FAAH (0.49) | FAAHSMN1; SMN2ROCK2PRKG1KIT | |
| SCHEMBL4089386 | 1.00 | FAAH (0.49) | FAAHSMN1; SMN2ROCK2PRKG1KIT | |
| SCHEMBL4075585 | 0.89 | GRIN2B (0.56) | FAAHCNR1GRIN2BCNR2 | |
| SCHEMBL5785037 | 0.82 | CNR1 (0.48) | FAAHCNR1CNR2 | |
| SCHEMBL5782006 | 0.82 | CNR1 (0.48) | FAAHCNR1CNR2 | |
| SCHEMBL4083275 | 0.81 | FAAH (0.52) | FAAHCNR1CNR2 | |
| SCHEMBL4075719 | 0.81 | GRIN2B (0.62) | FAAHSMN1; SMN2CNR1GRIN2BMEN1 | |
| SCHEMBL4079038 | 0.81 | GRIN2B (0.62) | FAAHSMN1; SMN2CNR1GRIN2BMEN1 | |
| SCHEMBL4084842 | 0.81 | FAAH (0.53) | FAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000748-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2024-01-04 | — | — | US | disclosed |
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000748-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | CNR1, CNR2, FAAH | FAAH 3/4885SMN1; SMN2 1729/4885ROCK2 3330/4885 |
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | CNR1, CNR2, FAAH | FAAH 3/4885SMN1; SMN2 1729/4885ROCK2 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.